Improved Progression-Free Survival for Bulky and Non-Bulky Advanced Stage Diffuse Large B-Cell Lymphoma with Consolidative Radiation Therapy: A Bi-Institutional Analysis

Yusef Ali Syed  
Emory University School of Medicine

Cecilia Jiang  
University of Pennsylvania

Jeffrey Switchenko  
Emory University

Khadija Kirmani  
Lipscomb University

Chris Kelsey  
Duke University

Mohammad K Khan (✉️ m.k.khan@emory.edu)  
Emory University Winship Cancer Institute

Research

Keywords: Non-Hodgkin's, Rituximab, R-CHOP, Adjuvant, Involved site, IMRT

DOI: https://doi.org/10.21203/rs.3.rs-137697/v1

License: ©️ This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

Background: The role of consolidative radiation therapy (RT) for advanced stage diffuse large B-cell lymphoma (DLBCL) is not fully established. Retrospective data provide evidence for the use of consolidative RT in stage III-IV DLBCL and emerging data from randomized studies address the role of RT in bulky disease for these patients.

Methods: Patient with stage III-IV DLBCL treated at two institutions who achieved clinical complete response to systemic therapy were included. Kaplan-Meier analysis was performed to determine the impact of consolidative RT. Univariate and multivariable analyses were performed using a Cox proportional hazards model.

Results: One hundred eighty-eight patients received systemic therapy consisting of R-CHOP (79%), another Rituximab-based regimen (9%), or chemotherapy alone (12%). Clinical response was assessed using conventional CT or PET-CT. Sixty-eight patients (36%) received consolidative RT (median dose 30 Gy). Consolidative RT conferred a 36.7% absolute benefit in five-year progression-free survival (85.9% vs. 49.2%, log rank p < 0.0001), and a 14.5% absolute benefit in five-year overall survival (87.4% vs. 72.9%, log rank p = 0.0134). On multivariable analysis, consolidative RT was associated with improved PFS (HR 0.23, 95% CI 0.10-0.52, p < 0.001). Patients receiving consolidative RT demonstrated significantly improved PFS for tumors measuring both <5 cm (log rank p = 0.0454) and ≥5 cm (log rank p = 0.0003).

Conclusions: For patients with stage III-IV DLBCL who achieve clinical complete response after systemic therapy, consolidative RT improves PFS for all patients, including those with non-bulky disease. This benefit persists in the setting of rituximab-based systemic therapy.

Background:

Diffuse large B-cell lymphoma (DLBCL) is the most common aggressive non-Hodgkin lymphoma and a majority of these patients present with stage III-IV disease. Systemic immuno-chemotherapy has significantly contributed to improving the survival rate and regimens consisting of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) have become the standard of care. Recently, other regimens have been introduced to address aggressive pathological features such as double or triple hit mutational status(1). Given that as many as two-thirds of patients present with advanced stage disease and 10-year overall survival for stage II-IV patients receiving R-CHOP alone is reported at 43.5%, further efforts are warranted to improve outcomes for this patient subset(2, 3).

In light of suboptimal patient outcomes consolidative radiation therapy (RT) at the completion of immunochemotherapy is regarded as an option for treatment escalation, though the strides made in systemic therapy have called into question the relative utility of RT. The RICOVER 60 trial showed a significant benefit in both event free survival and overall survival with the addition of radiation therapy in elderly patients with bulky disease, including those with advanced disease(4). For patients under 60 years
of age, additional evidence for treatment comes from a growing body of retrospective literature from Duke and MD Anderson Cancer Center, among others, that suggests a benefit with consolidative RT (5-7).

At present, patients with stage III-IV DLBCL standardly undergo 2-4 cycles of rituximab-based systemic therapy with interim restaging and completion of six cycles for those who demonstrate a response. Patients with bulky disease or limited skeletal involvement are often considered for consolidative RT, though prospective data are still forthcoming. Nonetheless, prior studies have shown that a majority of patients fail locally, particularly at sites of initially bulky disease, even after reaching clinical complete response (6, 8).

The aforementioned uncertainty with regards to the role of RT in advanced stage DLBCL has resulted in widely divergent practice patterns. Some institutions have elected to treat select stage III-IV patients, in particular those who present with bulky disease, exhibit partial response to chemotherapy, or demonstrate limited skeletal involvement at initial presentation. Still others resort to systemic therapy alone. As the exact role for consolidative radiotherapy in advanced stage DLBCL has yet to be fully elucidated, a subset of patients may be forgoing a potentially beneficial therapy at present. The data presented here build upon previously published work to further examine the potential benefits offered by consolidative RT.

**Methods:**

This bi-institutional retrospective study was approved by the Institutional Review Boards at Emory University and Duke University. Inclusion criteria consisted of patients diagnosed with stage III-IV DLBCL between April 1999 and January 2011 who had a documented clinical complete response to systemic therapy (cCR). Staging was determined based on the Ann Arbor classification system (9). Although the diagnostic modalities involved in staging varied by patient, the components generally included computed tomography (CT) of the chest, abdomen, and pelvis, bone marrow aspirate and biopsy, with positron emission tomography (PET) of the body used in a subset of cases. An International Prognostic Index (IPI) was also calculated for each patient and used as a prognostic variable (10). Bulky disease was defined as that measuring 5 cm or larger in maximal diameter based upon prior work finding this to be a meaningful cut point (11).

Patients were treated with a range of chemotherapy regimens, including rituximab combined with cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). Response was assessed based on CT or PET imaging and a cCR to systemic therapy as documented in imaging reports was necessary for inclusion in this study. Response was assessed using the International Harmonizing Project in Lymphoma criteria (12, 13). Those with incomplete response or refractory disease were excluded. Following cCR, a subset of patients was additionally treated with consolidative RT at the discretion of the treating medical and radiation oncologists. Patients were treated at either the Winship Cancer Institute at Emory University (Atlanta, GA) or the Duke Cancer Institute (Durham, NC). Patients were treated using 3D conformal RT or intensity modulated RT (IMRT) techniques delivered by conventional linear accelerators at both sites. Radiation therapy was generally given using modern principles of delivering treatment to
the original sites of disease with a small margin, though the RT protocol was not standardized across both institutions and was not a focus of this study. Clinical endpoints were measured from the date of diagnosis, as is customary for retrospective studies of this nature in which the timing and duration of treatments vary between patients.

**Statistical Methods**

Patients were divided into a chemotherapy-only cohort or chemotherapy plus RT cohort for analysis. Patient demographics, along with IPI score and bone or extranodal involvement were recorded. Numerical variables such as age at diagnosis were reported as median values with ranges. A chi-square test or Fisher's exact test were used to compare differences in categorical variables between cohorts, whereas differences in numerical covariates were compared with ANOVA. A p-value of less than 0.05 was considered statistically significant.

Patients were subsequently followed with disease recurrences documented to reflect location with respect to initial disease site(s) and radiation treatment fields in order to assess in-field local control (LC). LC at each timepoint was defined as an absence of radiographically or clinically apparent disease within radiation treatment fields, measured from the time of diagnosis to local failure. Those patients who did not experience local failure were censored at last follow-up. Other endpoints of interest included progression-free survival (PFS), defined from the date of diagnosis to the date of death or any disease progression, and overall survival (OS), defined from the date of diagnosis to the date of death or last follow-up. Patients who survived or experienced no disease progression were censored at the date of last follow-up.

Kaplan-Meier plots were generated for OS, PFS, and LC stratified by cohort, and a log-rank test was performed to assess for differences between cohorts with respect to the endpoints. 1-year, 2-year, and 5-year OS, PFS, and LC rates with 95% confidence intervals (CI) were also calculated separately by cohort. Additionally, a univariate Cox proportional hazard model was performed to assess for the effect of selected categorical covariates on LC, PFS, and OS. Multivariable Cox proportional hazard models were performed for PFS and OS. For local failure a multivariate analysis was not performed given the overall low number of events. All statistical analysis was performed using SAS Version 9.4 (Cary, NC).

**Results:**

A total of 287 patients received systemic therapy for confirmed DLBCL. After excluding patients who did not have stage III-IV disease at the time of treatment or did not demonstrate complete response to systemic therapy, 188 patients meeting inclusion criteria remained and comprised the study population. Of these, 79 patients were treated at Duke and 109 patients were treated at Emory. Stage III DLBCL comprised 36% of patients compared to 64% with stage IV disease. R-CHOP was administered to 79% of patients, while 9% received another rituximab-based regimen, and 12% were treated without rituximab. Staging was completed using PET-CT in 76 cases (40%), with conventional CT alone used in the remaining cases.
## Table 1
Patient demographics.

| Covariate                  | Value   | No N=120 N (%) | Yes N=68 N (%) | P-value* |
|----------------------------|---------|----------------|----------------|----------|
| **Radiation**              |         |                |                |          |
| Study site                 | Emory   | 79 (65.83)     | 30 (44.12)     | 0.004    |
|                            | Duke    | 41 (34.17)     | 38 (55.88)     |          |
| **Gender**                 |         |                |                |          |
|                            | Female  | 59 (49.17)     | 31 (45.59)     | 0.637    |
|                            | Male    | 61 (50.83)     | 37 (54.41)     |          |
| **ECOG**                   | 0       | 62 (52.1)      | 42 (62.69)     | 0.343    |
|                            | 1       | 52 (43.7)      | 22 (32.84)     |          |
|                            | 2/3     | 5 (4.2)        | 3 (4.48)       |          |
| **IPI**                    | 1       | 19 (15.83)     | 9 (13.24)      | 0.087    |
|                            | 2       | 35 (29.17)     | 26 (38.24)     |          |
|                            | 3       | 39 (32.5)      | 27 (39.71)     |          |
|                            | 4/5     | 27 (22.5)      | 6 (8.82)       |          |
| **Stage**                  | 3       | 45 (37.5)      | 23 (33.82)     | 0.614    |
|                            | 4       | 75 (62.5)      | 45 (66.18)     |          |
| **Size of largest site**   | <5cm    | 46 (47.42)     | 18 (31.03)     | 0.045    |
|                            | >5cm    | 51 (52.58)     | 40 (68.97)     |          |
| **B symptoms**             | No      | 67 (55.83)     | 45 (66.18)     | 0.165    |
|                            | Yes     | 53 (44.17)     | 23 (33.82)     |          |
| **LDH**                    | Normal  | 26 (27.37)     | 14 (25.45)     | 0.798    |
|                            | Above normal | 69 (72.63) | 41 (74.55)     |          |
| **Extranodal sites**       | No      | 23 (19.49)     | 17 (25)        | 0.379    |
|                            | Yes     | 95 (80.51)     | 51 (75)        |          |
| **BM involvement**         | No      | 87 (75)        | 51 (78.46)     | 0.600    |
|                            | Yes     | 29 (25)        | 14 (21.54)     |          |
| **Chemotherapy regimen**   | R-CHOP  | 95 (79.17)     | 53 (77.94)     | 0.079    |
In total, 68 patients (36%) received consolidative radiotherapy after systemic therapy while 120 patients (64%) received systemic therapy alone. Patient characteristics divided by cohort are depicted in Table 1. For those who received consolidative RT, patients were treated to a median of 30 Gy (range 12 Gy to 40.8 Gy) at 1.5 to 3 Gy per fraction. Patients with bulky disease (³5 cm), were more likely to receive consolidative RT (69% of radiation patients had bulky disease compared to 53% of non-radiation patients, p = 0.045), though no other significant differences between cohorts were noted. Patients treated at Duke were more likely to receive RT than those treated at Emory (48% vs. 28%, p = 0.004).

The median follow-up for the study population was 4.1 years. Patients receiving consolidative RT demonstrated significantly improved OS and PFS compared to the chemotherapy cohort on Kaplan-Meier analysis. Median OS was 6.6 years for the chemotherapy-only cohort and was not reached for the consolidative RT cohort. Median PFS was 4.9 years for the chemotherapy-only cohort and not reached for the consolidative RT cohort. With the addition of radiation, there was a 36.7% absolute benefit in five-year PFS (85.9% vs. 49.2%, log rank p < 0.0001), and a 14.5% absolute benefit in five-year OS (87.4% vs. 72.9%, log rank p = 0.0134). LC was numerically improved at five years with RT (94.0% vs. 86.9%, log rank p = 0.2477) though this did not reach statistical significance, largely due to a low number of local failures in both groups (3 local failures in the RT cohort vs. 12 in the no-RT cohort).

On univariate analysis three variables were associated with OS: use of RT vs. no RT (HR 0.38, p = 0.017), IPI 4/5 vs IPI 1 (HR 3.75, p = 0.043), and R-other vs. R-CHOP (HR 2.81, p = 0.015). Use of RT was also associated with improved PFS (HR 0.22, p < 0.001). On multivariable analysis the association between RT and PFS persisted (HR 0.23, 95% CI 0.10-0.52, p < 0.001) when adjusting for differences in IPI, tumor size,
systemic therapy regimen, and extranodal involvement. However, the association between consolidative RT and OS was reduced when adjusting for these same co-variables (HR 0.55, 95% CI 0.21-1.42, p = 0.216). The association between consolidative RT and LC failed to reach statistical significance on univariate analysis.

Table 2
Univariate and multivariable analysis for OS and PFS.

|                        | Univariate analysis | Multivariable analysis |
|------------------------|---------------------|------------------------|
|                        | HR  | p-value | HR  | 95% CI   | p-value |
| Overall survival       |     |         |     |          |         |
| Radiation Y vs. N      | 0.38 | 0.017   | 0.55 | 0.21-1.42 | 0.216   |
| IPI 4/5 vs. 1          | 3.75 | 0.043   | 2.34 | 0.56-9.82 | 0.245   |
| IPI 3 vs. 1            | 2.80 | 0.103   | 1.79 | 0.47-6.79 | 0.395   |
| IPI 2 vs. 1            | 1.43 | 0.589   | 1.09 | 0.26-4.55 | 0.909   |
| Tumor size >5 vs. <5 (cm) | 0.84 | 0.627   | 0.92 | 0.43-1.94 | 0.816   |
| No R vs. R-CHOP        | 0.57 | 0.276   | 0.50 | 0.15-1.66 | 0.260   |
| R others vs. R-CHOP    | 2.81 | 0.015   | 1.56 | 0.55-4.38 | 0.402   |
| Extranodal sites Y vs. N | 1.54 | 0.299   | 0.91 | 0.35-2.38 | 0.853   |
| Progression-free survival |     |         |     |          |         |
| Radiation Y vs. N      | 0.22 | <0.001  | 0.23 | 0.10-0.52 | <0.001  |
| IPI 4/5 vs. 1          | 1.29 | 0.517   | 0.81 | 0.30-2.17 | 0.679   |
| IPI 3 vs. 1            | 1.21 | 0.596   | 1.05 | 0.44-2.51 | 0.910   |
| IPI 2 vs. 1            | 0.87 | 0.710   | 0.69 | 0.27-1.77 | 0.438   |
| Tumor size >5 vs. <5 (cm) | 1.43 | 0.217   | 1.80 | 1.01-3.22 | 0.048   |
| No R vs. R-CHOP        | 0.62 | 0.216   | 0.85 | 0.35-2.06 | 0.724   |
| R others vs. R-CHOP    | 1.85 | 0.087   | 1.45 | 0.61-3.42 | 0.397   |
| Extranodal sites Y vs. N | 1.52 | 0.176   | 1.61 | 0.74-3.49 | 0.231   |

The impact of consolidative radiation with respect to tumor size was explored by prospectively setting a threshold maximal tumor diameter of 5 cm for the largest mass observed on initial staging imaging.
Patients receiving consolidative RT demonstrated significantly improved PFS for disease measuring both <5 cm (log rank p = 0.0454) and ≥5 cm (log rank p = 0.0003) in maximal diameter. No differences in OS or LC were observed with respect to tumor size at a threshold of 5 cm. Multivariable analysis also showed tumor size ≥5 cm vs. <5 cm to be associated with worse PFS (HR 1.80, 95% CI 1.01-3.22, p = 0.048).

**Discussion:**

The addition of consolidative RT for advanced stage DLBCL patients who demonstrate complete response after chemotherapy is associated with a statistically significant improvement in overall survival and progression free survival when pooling data from two academic medical centers. This analysis provides additional basis for the utilization of consolidative RT in these patients and contributes to a growing body of prospective and retrospective work. The combined data corroborate earlier retrospective studies, which collectively document improvements in overall survival, event free survival, progression-free survival, and in-field control with consolidative RT. Forthcoming randomized data are expected to further elucidate the role of RT for this group. Historically, stage III-IV patients have often been aggregated with stage I-II patients, potentially diluting any measurable benefit associated with consolidative RT. Thus, the true role for consolidative RT in this population is evolving.

Phan et al. previously reported statistically significant improvements in both OS and PFS at 5 years for a large cohort of DLBCL patients, consistent with the results presented here. The majority of patients in the Phan cohort presented with stage III-IV disease (279 from a total of 469), however, RT was delivered to only 39 (14%) advanced stage patients in their analysis as compared with 53 (28%) of patients in our cohort. OS and PFS were both significantly improved for advanced stage patients. They report 5-year OS and PFS after RT of 89% and 76%, respectively, as compared with our figures of 87% and 86%, respectively, at the same time point. Dorth et al. report excellent in-field control and event free survival for stage III-IV patients at 5 years with consolidative RT (92% and 85%, respectively). They reported a 5-year OS survival of 85% for RT patients and demonstrated a trend towards improvement but fell short of achieving statistical significance (78% for the no-RT subset, p = 0.15). The addition of advanced stage Emory patients bolstered the case for an OS advantage, though failed to meet criteria for significance on multivariable analysis likely due to confounding factors related to patient selection, tumor size, and sample size. Nonetheless, our combined Kaplan-Meier analysis demonstrated a clinically meaningful 14.5% improvement at 5 years with the pooled results. While the combined analysis failed to achieve statistical significance with respect to local control, it is reassuring that the overall number of local failures is low (15 events in total) and numerically improved with the addition of consolidative RT (3 vs. 12).

The definition of bulky disease from the standpoint of consolidation is a topic of ongoing debate, but the existing body of literature points to tumor size affecting treatment outcomes. Post-hoc analysis of the MlnT study found cut-off sizes of 6 cm and 10 cm corresponded to statistically significant differences in OS and EFS, respectively, among patient treated with R-CHOP and consolidative RT (14, 15). Additionally, prior work by our group has demonstrated a 5 cm cut-point to be meaningful with respect to local
control(11). This analysis builds upon these prior findings by demonstrating a PFS benefit that not only persists with a 5 cm cut-off point, but also applies to smaller tumors, a question that has not been addressed by prior work. The results presented here support extending consolidative RT to a larger subset of advanced stage DLBCL patients.

The advent of rituximab substantially improved survival outcomes for lymphoma patients, firmly establishing R-CHOP as the standard of care for DLBCL(2, 15-17). This has led some to question the utility of consolidative RT, particularly as it exposes patients to a separate array of potential toxicities. Thus, the therapeutic effect of consolidative RT, specifically for patients receiving R-CHOP, was of particular interest in our analysis as well as in the other studies described here. Fully 84% percent of MDACC patients and 88% of patients in the Emory/Duke combined cohort received a complete or partial course of rituximab-based systemic therapy. Results from these three centers demonstrate a substantial and clinically meaningful benefit for consolidative RT in patients treated with rituximab, corroborating results of a recent NCCN outcomes database analysis for DLBCL patients across all stages(18).

The results presented here complement prior retrospective studies and support further investigations of consolidative RT in stage III-IV DLBCL. The RICOVER-60 trial included DLBCL patients across all stages and primarily evaluated the addition of rituximab to six versus eight cycles of CHOP-14, with consolidative RT delivered to sites of initially bulky (³7.5 cm) or extralymphatic disease. The impact of RT was later examined by means of a protocol amendment that created a no-RT arm that was not included in the initial randomization. The intent-to-treat analysis showed improved event-free survival and a trend towards improved PFS and OS (the latter two were significantly improved in the per-protocol analysis). The ongoing UNFOLDER trial, published in abstract form, randomized a similar group of patients to two R-CHOP regimens with a second randomization to consolidative RT to bulky and extra-nodal disease(19). Of note, the no-RT arm was closed at interim analysis. Additionally, results from the OPTIMAL>60 trial were published in abstract form and suggest that for elderly patients RT can be spared in bulky disease that is PET-negative after chemotherapy, though patients with persistent disease received RT per protocol(20).

Aside from radiation therapy, other consolidation strategies have been explored for advanced stage DLCL. The randomized, phase II GELA/LYSA trial sought to evaluate the efficacy of two rituximab-based induction regimens along with a PET-driven consolidation regimen(21). According to this protocol, patients with negative PET-CT after completion of 4 cycles of induction therapy (PET4) were treated based upon an interim PET-CT completed after 2 induction cycles (PET2); patients with negative PET2 received consolidative immunochemotherapy while those with positive PET2 received chemotherapy and autologous stem cell transplant (ASCT). For patients treated with induction R-CHOP who exhibited cCR, 4-year results show a PFS of 82.2% and OS of 87.2%. These figures compare favorably with results presented here for consolidative RT (85.9% and 87.4%, respectively at 5 years), suggesting that radiation therapy may be a reasonable alternative to additional immunochemotherapy or ASCT.
One shortcoming of our work is that RT dosing varied significantly across patients in our study cohort with a median dose of 30 Gy, which is lower than doses utilized in many previous large randomized trials of consolidative IFRT in stage I-II non-Hodgkin lymphoma; SWOG 8736 used 40-55 Gy, while LHN 93-1 and 93-4 used 40 Gy, though ECOG 1484 did use 30 Gy (22-25). These trials were conducted in the pre-rituximab era and a subsequent meta-analysis incorporating selected data from these four trials revealed a PFS improvement with IFRT but failed to demonstrate improvement in OS. This meta-analysis was limited by heterogeneity in the pooled dataset, however (26). For patients with advanced disease who respond well to systemic therapy it has been suggested that lower RT doses may, in fact, be preferred since these patients are likely to have received longer courses of chemotherapy and RT will be delivered to larger volumes (27). As such, 30 Gy is regarded as a standard dose at this time.

Other shortcomings include the non-standardization of imaging in response assessment and the age of our dataset. It is now established that PET-CT is the gold standard in the staging of aggressive NHL and has higher specificity, accuracy and positive predictive value in detecting residual disease after systemic therapy than CT alone, though this practice was not established when some of our earlier patients were diagnosed (28, 29). While PET-CT was utilized in many cases, this was not a strict requirement for patients in this combined dataset. As such, were not able to derive meaningful associations related to specific imaging findings, such as Deauville (5 point) score or SUV values as demonstrated previously (11). Finally, concerning our timeline, advances in radiation oncology, including image guidance and volumetric dose planning, have improved the quality of care since the time that our earliest patients received treatment.

**Conclusion:**

For patients with stage III-IV DLBCL who achieve clinical complete response after systemic therapy, this retrospective, bi-institutional analysis demonstrates that consolidative RT improves progression free survival for all patients, including those with non-bulky disease. This benefit persists in the setting of rituximab-based systemic therapy.

**Declarations:**

**Ethics approval and consent to participate:**

All work was previously approved by the Institutional Review Boards at each participating institution.

**Consent for publication:**

Not applicable

**Availability of data and materials:**
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

**Competing interests:**

The authors declare that they have no competing interests.

**Funding Statement:**

The authors received no specific funding for this work.

**Authors’ contributions:**

YS interpreted the outcomes data and was a major contributing author, CJ edited the dataset and was a minor contributing author, JS performed all statistical analyses and edited the manuscript, KK assisted in composing the database, CK supervised all data collection at Duke University, interpreted outcomes data, and edited the manuscript, MK supervised all data collection at Emory University and edited the manuscript.

**Acknowledgements:**

Research reported in this publication was supported in part by the Biostatistics Shared Resource of Winship Cancer Institute of Emory University and NIH/NCI under award number P30CA138292. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

**References:**

1. Dunleavy K, Pittaluga S, Maeda LS, Advani R, Chen CC, Hessler J, et al. Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma. N Engl J Med. 2013;368(15):1408-16.
2. Coiffier B, Thieblemont C, Van Den Neste E, Lepeu G, Plantier I, Castaigne S, et al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d’Etudes des Lymphomes de l’Adulte. Blood. 2010;116(12):2040-5.
3. Ng AK, Yahalom J, Goda JS, Constine LS, Pinnix CC, Kelsey CR, et al. Role of Radiation Therapy in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Guidelines from the International Lymphoma Radiation Oncology Group. Int J Radiat Oncol Biol Phys. 2018;100(3):652-69.
4. Held G, Murawski N, Ziepert M, Fleckenstein J, Poschel V, Zwick C, et al. Role of radiotherapy to bulky disease in elderly patients with aggressive B-cell lymphoma. J Clin Oncol. 2014;32(11):1112-8.
5. Dorth JA, Prosnitz LR, Broadwater G, Diehl LF, Beaven AW, Coleman RE, et al. Impact of consolidation radiation therapy in stage III-IV diffuse large B-cell lymphoma with negative post-chemotherapy radiologic imaging. Int J Radiat Oncol Biol Phys. 2012;84(3):762-7.
6. Ferreri AJ, Dell'Oro S, Reni M, Ceresoli GL, Cozzarini C, Ponzoni M, et al. Consolidation radiotherapy to bulky or semibulky lesions in the management of stage III-IV diffuse large B cell lymphomas. Oncology. 2000;58(3):219-26.

7. Phan J, Mazloom A, Medeiros LJ, Zreik TG, Wogan C, Shihadeh F, et al. Benefit of consolidative radiation therapy in patients with diffuse large B-cell lymphoma treated with R-CHOP chemotherapy. J Clin Oncol. 2010;28(27):4170-6.

8. Shi Z, Das S, Okwan-Duodu D, Esiashvili N, Flowers C, Chen Z, et al. Patterns of failure in advanced stage diffuse large B-cell lymphoma patients after complete response to R-CHOP immunochemotherapy and the emerging role of consolidative radiation therapy. Int J Radiat Oncol Biol Phys. 2013;86(3):569-77.

9. Carbone PP, Kaplan HS, Musshoff K, Smithers DW, Tubiana M. Report of the Committee on Hodgkin's Disease Staging Classification. Cancer Res. 1971;31(11):1860-1.

10. International Non-Hodgkin's Lymphoma Prognostic Factors P. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med. 1993;329(14):987-94.

11. Jegadeesh N, Rajpara R, Esiashvili N, Shi Z, Liu Y, Okwan-Duodu D, et al. Predictors of local recurrence after rituximab-based chemotherapy alone in stage III and IV diffuse large B-cell lymphoma: guiding decisions for consolidative radiation. Int J Radiat Oncol Biol Phys. 2015;92(1):107-12.

12. Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25(5):579-86.

13. Juweid ME, Stroobants S, Hoekstra OS, Mottaghy FM, Dietlein M, Guermazi A, et al. Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol. 2007;25(5):571-8.

14. Pfreundschuh M, Ho AD, Cavallin-Stahl E, Wolf M, Pettengell R, Vasova I, et al. Prognostic significance of maximum tumour (bulk) diameter in young patients with good-prognosis diffuse large-B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: an exploratory analysis of the MabThera International Trial Group (MInT) study. Lancet Oncol. 2008;9(5):435-44.

15. Pfreundschuh M, Kuhnt E, Trümper L, Österborg A, Tmeny M, Shepherd L, et al. CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group. The Lancet Oncology. 2011;12(11):1013-22.

16. Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346(4):235-42.

17. Coiffier B, Pfreundschuh M, Stahel R, Vose J, Zinzani PL. Aggressive lymphoma: improving treatment outcome with rituximab. Anticancer Drugs. 2002;13 Suppl 2:S43-50.
18. Dabaja BS, Vanderplas AM, Crosby-Thompson AL, Abel GA, Czuczman MS, Friedberg JW, et al. Radiation for diffuse large B-cell lymphoma in the rituximab era: analysis of the National Comprehensive Cancer Network lymphoma outcomes project. Cancer. 2015;121(7):1032-9.

19. Held G, Thurner L, Poeschel V, Berdel C, Ott G, Schmidt C, et al. Role of radiotherapy and dose-densification of R-CHOP in primary mediastinal B-cell lymphoma: A subgroup analysis of the unfolder trial of the German Lymphoma Alliance (GLA). Journal of Clinical Oncology. 2020;38(15_suppl):8041-.

20. Pfreundschuh M, Christoyllakis K, Altmann B, Ziepert M, Haenel M, Viardot A, et al. Radiotherapy to bulky disease PET-negative after immunochemotherapy in elderly DLBCL patients: Results of a planned interim analysis of the first 187 patients with bulky disease treated in the OPTIMAL>60 study of the DSHNHL. Journal of Clinical Oncology. 2017;35(15_suppl):7506-.

21. Casasnovas RO, Ysebaert L, Thieblemont C, Bachy E, Feugier P, Delmer A, et al. FDG-PET-driven consolidation strategy in diffuse large B-cell lymphoma: final results of a randomized phase 2 study. Blood. 2017;130(11):1315-26.

22. Miller TP, Dahlberg S, Cassady JR, Adelstein DJ, Spier CM, Grogan TM, et al. Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin's lymphoma. N Engl J Med. 1998;339(1):21-6.

23. Reyes F, Lepage E, Ganem G, Molina TJ, Brice P, Coiffier B, et al. ACVBP versus CHOP plus radiotherapy for localized aggressive lymphoma. N Engl J Med. 2005;352(12):1197-205.

24. Horning SJ, Weller E, Kim K, Earle JD, O’Connell MJ, Habermann TM, et al. Chemotherapy with or without radiotherapy in limited-stage diffuse aggressive non-Hodgkin's lymphoma: Eastern Cooperative Oncology Group study 1484. J Clin Oncol. 2004;22(15):3032-8.

25. Bonnet C, Fillet G, Mounier N, Ganem G, Molina TJ, Thieblemont C, et al. CHOP alone compared with CHOP plus radiotherapy for localized aggressive lymphoma in elderly patients: a study by the Groupe d’Etude des Lymphomes de l’Adulte. J Clin Oncol. 2007;25(7):787-92.

26. dos Santos LV, Lima JP, Lima CS, Sasse EC, Sasse AD. Is there a role for consolidative radiotherapy in the treatment of aggressive and localized non-Hodgkin lymphoma? A systematic review with meta-analysis. BMC Cancer. 2012;12:288.

27. Kelsey CR, Beaven AW, Diehl LF, Prosnitz LR. Radiation therapy in the management of diffuse large B-cell lymphoma: still relevant? Oncology (Williston Park). 2010;24(13):1204-12.

28. D’Souza M M, Jaimini A, Bansal A, Tripathi M, Sharma R, Mondal A, et al. FDG-PET/CT in lymphoma. Indian J Radiol Imaging. 2013;23(4):354-65.

29. Barrington SF, Mikhaeel NG, Kostakoglu L, Meignan M, Hutchings M, Mueller SP, et al. Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group. J Clin Oncol. 2014;32(27):3048-58.
Figure 1

Kaplan-Meier plot for overall survival for the study cohort.
Figure 2

Kaplan-Meier plot for progression free survival for the study cohort.
Figure 3

Kaplan-Meier plot for local control for the study cohort.
Figure 4

Kaplan-Meier plot for progression free survival for patients with tumors <5 cm in maximal diameter.
Figure 5

Kaplan-Meier plot for progression free survival for patients with tumors $\geq 5$ cm in maximal diameter.